AGTC Expands Management Team with Two Key Hires

GAINESVILLE, Fla.--(BUSINESS WIRE)--AGTC, a clinical stage biotechnology company announced that the company has hired two new management team members, Daniel L. Menichella and Frank Sprecher. Both bring a wealth of previous leadership experience in the pharmaceutical and biotech industries. Daniel L. Menichella will serve as AGTC's new Vice President and Chief Business Officer and Frank Sprecher joins as the company's Project Director.

"We are thrilled to expand our team with Dan and Frank to meet AGTC's ever growing business demands," said Sue Washer, President and CEO of AGTC. "AGTC is already recognized as a world leader in innovative gene therapy treatments for rare eye and lung diseases. In addition to the diverse experience and expertise Dan and Frank bring, they have a passion for excellence that has long been the hallmark of AGTC's success. These strategic hires position AGTC for success as the company continues to expand."

Dan Menichella brings more than 20 years' experience in life sciences corporate development. Most recently he served as Chief Business Officer of Zyngenia, Inc. in Gaithersburg, Maryland. Prior, he served as Senior Vice President Corporate Business Development and Strategy for Talecris Biopharmaceuticals, and has held business development and strategy positions for companies such as Merck KGaA, MorphoSys USA/AG and Novartis. Menichella holds a Bachelor of Arts degree from Harvard University and a Master of Business Administration from the University of North Carolina at Chapel Hill and is on the Board of Paloma Pharmaceuticals, a Boston based biotechnology company.

Frank Sprecher joins the team with a proven track record of establishing and implementing strategic and process improvement initiatives to support new product development, portfolio prioritization and budgeting and forecasting. Previously, Sprecher was the Director of Corporate Project Management at Forest Laboratories in New Jersey, where he lead product development teams encompassing Phase II through Life Cycle Management. Sprecher has an MBA with focus in financial management and a Bachelor of Science degree in biological sciences from Drexel University.

About AGTC

AGTC is a privately held, clinical-stage biotechnology company creating first-in-class treatments for rare eye and lung diseases caused by mutated genes. The company currently has five programs in development from pre-clinical through Phase 2. A leader in gene therapy treatments, AGTC uses a safe and effective delivery system, the adeno-associated virus (AAV). A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide. AGTC is headquartered in Alachua, FL. For more information, please visit www.agtc.com.

Contacts

Lazar Partners
Stephanie Marks, 212-867-1762
[email protected]

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.